Table 1 Baseline patient characteristics and treatment
From: Potency preservation following stereotactic body radiation therapy for prostate cancer
Patients (n = 97) | ||
|---|---|---|
Age (years) | Age ≤ 60 | 14 (14.4%) |
|  | 60 < Age ≤ 70 | 55 (56.7%) |
|  | Age > 70 | 28 (28.9%) |
Race | Â | Â |
| Â | White | 47 (48.5%) |
| Â | Black | 46 (47.4%) |
| Â | Other | 4 (4.1%) |
Median Pre- Tx PSA (ng/ mL) Median | Â | 5.9 (1.8-32.5)ng/mL |
Median Pre- Tx testosterone (nmol/ L) | Â | 11.4 (4.4-27.9)nmol/L |
Partner status | Â | Â |
| Â | Partnered | 73 (75.3%) |
| Â | Not partnered | 24 (24.7%) |
Charlson comorbidity index (CCI) | Â | Â |
| Â | 0 | 78 (80.4%) |
| Â | 1 | 13 (13.4%) |
| Â | 2 | 5 (5.2%) |
| Â | 3 | 1 (1%) |
Body mass index (BMI) | Â | Â |
| Â | <25 | 24 (24.7%) |
| Â | 25-29.99 | 46 (47.4%) |
| Â | 30-34.99 | 23 (23.7%) |
|  | ≥ 35 | 4 (4.1%) |
Risk group (D’ Amico’ s) |  |  |
| Â | Low risk | 43 (44.3%) |
| Â | Intermediate risk | 50 (51.5%) |
| Â | High risk | 4 (4.1%) |
Work status | Â | Â |
| Â | Working | 57 (58.8%) |
| Â | Non-working | 40 ((41.2%) |
Pre-treatment SHIM score | Â | Â |
| Â | 22-25 (No ED) | 49 (50.5%) |
| Â | 17-21 (Mild ED) | 32 (33.0%) |
| Â | 12-16 (Mild Moderate ED) | 10 (10.3%) |
| Â | 8-11 (Moderate ED) | 2 (2.1%) |
| Â | < 8 (Severe ED) | *(No Sexual Activity) 4 (4.1%) |
Sexual aid | Â | Â |
| Â | None | 62 (63.9%) |
| Â | Oral | 35 (36.1%) |
| Â | Vacuum | 1 (1.0%) |
| Â | Suppository/injection | 0 (0%) |
Dose (Gy) | Â | Â |
| Â | 36.25 | 87 (89.7%) |
| Â | 35 | 9 (9.3%) |
| Â | Other | 1 (1.0%) |